VERY LOWa, b, c due to risk of bias, indirectness, imprecision Moderate (from 27 fewer to 1000 more) Permanent study drug discontinuation LOW b due to imprecision (from 78 fewer to 107 more) Adverse events (not described) 225 VERY LOWa, b, c due to risk of bias, indirectness, imprecision (from 146 fewer to 99 more) Serious adverse events (not described) VERY LOWa, b, c due to risk of bias, indirectness, imprecision (from 44 fewer to 136 more) Change in peak VO2 ml/kg/min 225 LOW a,d due to risk of bias - The median change in peak VO2 in the placebo group was ml/kg/min The median change in peak VO2 in the oral iron group was Change in 6-minute walk test distance (m) LOWa,d due to risk of bias - The median walk test distance in The median 6 minute walk test distance in the oral iron group was Treating Heart Failure Chronic Heart Failure NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: Outcomes No of Participants (studies) Follow up Quality of the evidence (GRADE) Relative effect Anticipated absolute effects Risk with Placebo Risk difference with Oral iron (95% CI) the placebo group was Change in KCCQ clinical summary score (Higher score indicates better outcome) LOW a,d due to risk of bias - The median KCCQ in the placebo group was The median KCCQ clinical summary score in the oral iron group was (a) Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias . (b) Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs . 